Let’s Work Together.

Aytu seeks to in-license and acquire assets to build on our current areas with a distinct focus on CNS-related conditions. In collaborating with our partners, we aim to be the partner-of-choice while building a portfolio that addresses the needs of patients and physicians.

We are primarily interested in late-stage and approved medications, and our objective is to make a meaningful impact on patients’ lives while building successful partnerships. We are also interested in out-licensing our ADHD brands to partners in markets outside the United States.